연구성과로 돌아가기

2024 연구자 정보 (53 / 1079)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Yadav, Monica
(Yadav, M)


[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer
[JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC)
[JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria
[JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC)
[JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study
SCIE 1.7 ONCOLOGY
Yang, Sheng-Shun
(Yang, SS)
Taichung Vet Gen Hosp, Taichung, Taiwan

[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY limys@amc.seoul.kr;
Yi, Kiyoun
(Yi, K)
Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea
Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
Pusan Natl Univ, Pusan Natl Univ Hosp, Coll Med, Pusan, South Korea


[JCR상위 1.7] Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis
[JCR상위 4.4] BENEFICIAL EFFECT OF COMBINED RADIATION THERAPY IN ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT OF HEPATOCELLULAR CARCINOMA PATIENTS WITH MAIN PORTAL VEIN TUMOR THROMBOSIS OR BILE DUCT INVASION
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY jheo@pusan.ac.kr;
Yoo, Chang Hak
(Yoo, CH)
Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Surg, Sch Med, Seoul, South Korea

[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY SCIE 1.7 ONCOLOGY ykkang@amc.seoul.kr;
Yoo, Moon-Won
(Yoo, MW)
Univ Ulsan, Asan Med Ctr, Dept Surg, Seoul, South Korea

[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY SCIE 1.7 ONCOLOGY ykkang@amc.seoul.kr;
Yook, Jeong Hwan
(Yook, JH)
Univ Ulsan, Asan Med Ctr, Dept Surg, Seoul, South Korea

[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY SCIE 1.7 ONCOLOGY ykkang@amc.seoul.kr;
Yu, Jisang
(Yu, J)
Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
0000-0002-4370-947X
Yu, Jisang
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer
[JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria
[JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC)
[JCR상위 37.6] Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy
SCIE 1.7 ONCOLOGY YCHAE@nm.org;
Yu, Ming-Lung
(Yu, ML)
Natl Sun Yat Sen Univ, Kaohsiung, Taiwan C-9540-2009
Yu, Ming-Lung

[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY limys@amc.seoul.kr;
Yun, Kum-Hee
(Yun, KH)
Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea
0009-0006-5268-3191
Yun, Kum-Hee
[JCR상위 1.7] Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma
[JCR상위 7.0] Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
SCIE 1.7 ONCOLOGY
MULTIDISCIPLINARY SCIENCES
hyosong77@yuhs.ac;
Zang, Dae Young
(Zang, DY)
Hallym Univ, Dept Internal Med, Sacred Heart Hosp, Anyang, South Korea

[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY SCIE 1.7 ONCOLOGY ykkang@amc.seoul.kr;
Zanoletti, Alessandra
(Zanoletti, A)
교신저자 Univ Brescia, Dept Mech & Ind Engn, INSTM & Chem Technol Lab, Via Branze 38, I-25123 Brescia, Italy AAC-9945-2022
Zanoletti, Alessandra
0000-0003-0225-7048
Zanoletti, Alessandra
[JCR상위 1.7] Skin protection from solar ultraviolet radiation using natural compounds: a review SCIE 1.7 CHEMISTRY, MULTIDISCIPLINARY;ENVIRONMENTAL SCIENCES;ENGINEERING, ENVIRONMENTAL ankit.verma@mail.huji.ac.il;alessandra.zanoletti@unibs.it;2021321530@knu.ac.kr;adelodun.b@unilorin.edu.ng;kumarpankajgkv@gmail.com;foajibade@futa.edu.ng;lsilva8@cuc.edu.co;ankurphillips245@gmail.com;tkarthees@gmail.com;elza.bontempi@unibs.it;ashish.dwivedi1@iitr.res.in;
Zhang, Kai
(Zhang, K)


[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer
[JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC)
[JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study
SCIE 1.7 ONCOLOGY
Zheng, Tiantian
(Zheng, T)


[JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. SCIE 1.7 ONCOLOGY
Zotkiewicz, Magdalena
(Zotkiewicz, M)
AstraZeneca, Oncol Biometr, Late Oncol Stat, Warsaw, Poland

[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
[JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
SCIE 1.7 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY
bsangro@unav.es;
Chang, Mingi
(Chang, M)
제1저자 Kyungpook Natl Univ, Coll Nursing, Daegu, South Korea
0000-0003-1338-9396
Mingi, Chang
[JCR상위 1.8] Effects of a mobile-based bioterrorism response program among clinical nurses: A quasi-experimental study SCIE;SSCI 1.8 EDUCATION, SCIENTIFIC DISCIPLINES;NURSING yujeongkim@knu.ac.kr;
페이지 이동: